[1] |
SHE Zhihua, CHEN Zhou, LIANG Songyue.
Construction of informatization system of drug clinical trials ethical review based on cloud architecture
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1023-1030.
|
[2] |
CHE Jinjing, LI Na.
General considerations on bioanalytical methods for comparative evaluation of biosimilars immunogenicity
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 721-728.
|
[3] |
SUN Yuchen, LIU Yinhui, ZHANG Xian, YUAN Tong, JING Mengyao, ZAHNG Xinyu, YANG Jin.
Exploration of screening criteria for healthy volunteers in human bioequivalence clinical trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 714-720.
|
[4] |
ZHENG Lichun, WANG Xiang, WANG Wenmei.
Management strategies and suggestions on stomatological clinical trials under the influence of epidemic
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 213-216.
|
[5] |
PAN Wei-song, ZHOU Yong-biao, ZHANG Ne-min, XIAO Ying.
Study on the hemolysis causes of aminomethyl benzoic acid (PAMBA) injection
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(8): 878-883.
|
[6] |
LIU Mi-feng, PENG Shuang-qing, SHENG Zhi-guo, XIE Yue-hua, DONG Yan-sheng, YANG Haiying, HAN Gang, YAN Chang-hui.
Research on correlations between cytotoxicity and acute toxicity of seven compounds
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(1): 42-45.
|
[7] |
JIANG Xian-peng, Robert L.Elliott, Jonathan F.Head.
Transfer of interleukin 6 gene into MCF-7 human breast cancer cells enhances expression of tumor-associated antigens
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(3): 275-281.
|
[8] |
XU Xiao-guo, JIANG Meng, XIONG Ning-ning, ZOU Jian-dong, LIU Fang, GAO Wei-min.
Designing method of phase I tolerance trial of several traditional medications for external use in human body
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(2): 152-155.
|
[9] |
WU Cheng-yi, XIAO Feng, GAN Lei, XU Qiang, YU Xiao-qi, SHI Li, ZHENG Qing-shan, SUN Rui-yuan, WEI wei.
Tolerance of ulinastatin in healthy volunteers
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(1): 103-106.
|
[10] |
XU Feng-hua, FU Wei-jun, ZHANG Zhi-ping, WANG Xiao-xiong.
Experimental studies and evaluation on safety of compound aluminum sulfate injection
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(5): 510-514.
|
[11] |
XIAO Shu-Hua, WEI Guang-Li, LU Rong, LIU Chang-Xiao, WANG Feng-Peng.
Studies on toxicokinetics of single or combination administration of bromo-tetrandrine and adriamycin in beagle dogs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(11): 1221-1225.
|
[12] |
XIANG Nan, HU You-Zhi, SHI Jie, ZHANG Feng, FENG De-Xun.
Efficacy and safety of xindakang capsules in treatment of patients with angina pectoris
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(9): 1033-1036.
|
[13] |
WU Nan, WANG Ai-Ping.
Immunotoxicology applied in new drug safety assessment
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(8): 855-858.
|
[14] |
GUO Wei, CUI Jing-Rong.
Does selection of combination treatment of cisplatin and cyclophosphamide
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(7): 744-746.
|
[15] |
WANG Wen, MA Li-Yuan, ZOU Xiao-Man.
Monitoring in multicenter clinical trial
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(7): 835-837.
|